VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC.

Authors :: Schmid, P.
Cortes, J.
Dent, R.
Pusztai, L.
McArthur, H.
Kümmel, S.
Bergh, J.
Denkert, C.
Park, Y.H.
Hui, R.
Harbeck, N.
Takahashi, M.
Untch, M.
Fasching, P.A.
Cardoso, F.
Ding, Y.
Tryfonidis, K.
Aktan, G.
Karantza, V.
O'Shaughnessy, J.
Source :: Annals of Oncology. Sep2021, Vol. 32 Issue 9, p1198-1200. 3p.
Publication Year :: 2021

Subjects :: *ADJUVANT treatment of cancer
*TRIPLE-negative breast cancer
*PEMBROLIZUMAB
*CANCER chemotherapy
*PLACEBOS
*CANCER treatment

Full Text Access

Tools